

Review Article

The molecular genetics of Usher syndrome

Ahmed ZM, Riazuddin S, Riazuddin S, Wilcox ER. The molecular genetics of Usher syndrome.

Clin Genet 2003; 63: 431–444. © Blackwell Munksgaard, 2003

Association of sensorineural deafness and progressive retinitis pigmentosa with and without a vestibular abnormality is the hallmark of Usher syndrome and involves at least 12 loci among three different clinical subtypes. Genes identified for the more commonly inherited loci are *USH2A* (encoding usherin), *MYO7A* (encoding myosin VIIa), *CDH23* (encoding cadherin 23), *PCDH15* (encoding protocadherin 15), *USH1C* (encoding harmonin), *USH3A* (encoding clarin 1), and *USH1G* (encoding SANS). Transcripts from all these genes are found in many tissues/cell types other than the inner ear and retina, but all are uniquely critical for retinal and cochlear cell function. Many of these protein products have been demonstrated to have direct interactions with each other and perform an essential role in stereocilia homeostasis.

**ZM Ahmed^{a,b}, S Riazuddin^b,
S Riazuddin^a and ER Wilcox^{a,b}**

^aNational Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan; ^bLaboratory of Molecular Genetics, Section on Human Genetics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD, USA

Key words: deafness – retinitis pigmentosa – Usher syndrome – vestibular dysfunction

Corresponding author: Edward R. Wilcox, Laboratory of Molecular Genetics, Section on Human Genetics NIDCD, NIH 5 Research Court, 2A-19 Rockville, MD 20850-3227, USA. Tel.: +1 301 402 4612; fax: +1 301 480 8019; e-mail: wilcox@nidcd.nih.gov

Received 4 March 2003, revised and accepted for publication 28 March 2003

There are many syndromes that affect both the visual and auditory systems but Usher syndrome is the most common genetic cause of deafness and blindness among school age children (1–3). Usher syndrome was first described in 1858 (but not by name) when the German ophthalmologist Alfred von Graefe published an article describing a family in which deafness and blindness cosegregated (4). Kloepper and Laguaite provide an excellent review of the early literature regarding Usher syndrome (5). Its prevalence is currently estimated in developed countries at 3.8–4.4 per 100,000 live births (6,7) and is found much more commonly among those with retinitis pigmentosa than among those that are deaf (8, 9). Hearing loss is more prevalent than retinitis pigmentosa (estimated at 12.5–27.0 per 100,000 live births) in developed countries (10, 11). The prevalence of deafness among children in a developed country was recently estimated from a survey of deaf children in the United Kingdom (population 59 million) at 1.07 cases/1000 for 3 year olds to 2.05 for those aged 9–16 (12). Of those reported to be deaf, 5.7% also had problems in the visual system out of a total of 27.4% describing traits in addi-

tion to hearing loss (12, 13). These numbers are in agreement with surveys performed in the United States where it was found that at least 50% of those with hearing problems were genetic in origin (14).

The majority of patients with Usher syndrome usually fall into one of these clinically distinct categories. Usher syndrome type I (USH1) patients have profound hearing loss and vestibular dysfunction from birth. In addition, night blindness appears earlier in life than USH2 patients, who tend to have less severe hearing loss and normal vestibular function (15–17). A third classification (USH3) is found most frequently among Finnish patients where the hearing loss and retinitis pigmentosa are progressive, with variable vestibular dysfunction (18). Some patients affected with Usher syndrome cannot be easily categorized into one of three subtypes, these show an atypical clinical designation (19).

Usher syndrome is heterogeneous, which means that different mutated genes can cause the same phenotype. In Table 1 we list all known loci including those for which there are mouse models or genes cloned along with information on the

Table 1. Molecular classification of Usher syndrome

Usher locus	Chromosomal location	Overlapping non-syndromic locus	Gene	Protein	Mouse model	Relative abundance in a sampling of mostly US Usher patients	Relative abundance in a sampling of Pakistani deaf children
USH type I A (95) B (22)	14q32 11q13.5	— DFNB2 DFNA11 (48, 51, 97)	— MYO7A	— Myosin VIIa	Shaker 1 (56)	Relative to USH1 49% (50)	Relative to USH1 42.9%
C (23) D (26) E (96) F (27) G (28) ?	11p15.1 10q22.1 21q21 10q21.1 17q25.1 Unknown	DFNB18 (44) DFNB12 (43) — DFNB23 (42)? —	USH1C CDH23 — PCDH15 SANS	Harmonin Cadherin 23 — Protocadherin 15 SANS	Waltzer (74) Ames waltzer (79) Jackson shaker (82)	>2% (50) 33% (combined D&F, 50) 33% (combined F&D, 50) 16% (50) Relative to USH2 >70% (85)	12.2% 28.6% 12.2% 4.1%
USH type II A (20)	1q41	Non-syndromic RP(46)	USH2A	Usherin			
B (29) C (110) ? (85)	3p23-24.2 5q14.3-21.3 Unknown	DFNB6 (45)? — —	— — —	— — —			
USH type III A (18) B (64)	3q25.1 20q	— —	USH3A —	Clarin 1 —			

relative abundance of some of these loci. It is known from many years of research performed at the Boys Town National Research Hospital (Omaha, NE) that markers at 1q41 (*USH2A*) cosegregate with the phenotype in many USH2 families (20, 21) and markers at 11q13.5 (*USH1B*) cosegregate with the phenotype in many USH1 families (22). Other groups found that samples from USH1 families with an Acadian ancestry cosegregate with a locus at 11p15.1 (*USH1C*) (23, 24). It was then found that markers at 3q25 cosegregate with the phenotype in Finnish families inheriting USH3 (18). Families supporting sufficient statistical power to either refine known loci or to define new linkage locations have aided in the identification of several loci (25). *USH1D* was localized to chromosome 10q22.1 (26), *USH1F* was localized to 10q21.1 (27), *USH1G* was localized to 17q25.1 (28), and *USH2B* was localized to 3p23-24.2 (29).

Linkage data from over 400 Pakistani families is in agreement with these types of measurements assayed in other parts of the world. Approximately 10% of families enrolled in schools for deaf children have USH1. In relative abundance, almost half are linked to the *USH1B* locus followed by approximately 30% linked to *USH1D* and the remainder equally divided between *USH1C* and *USH1F* (unpublished data, SR, SR and ZMA, see Table 1).

Mutations in seven different genes are currently ascribed as the cause of Usher syndrome: *USH1B* encoding myosin VIIa (30), *USH1C* encoding harmonin (31, 32), *USH1D* encoding cadherin 23 (33, 34), *USH1F* encoding protocadherin 15 (35, 36), *USH1G* encoding SANS (37), *USH2A* encoding usherin (38), and *USH3A* encoding clarin-1 (39–41). These genes were identified through the discovery of a mouse homolog, or by positional cloning. Many of the Usher loci also overlap the same chromosomal location as loci responsible for non-syndromic deafness. Recessive non-syndromic deafness locus 12 (*DFNB12*) (42) mapped to the same region of chromosome 10 as *USH1D* (26, 43), *DFNB18* to *USH1C* (23, 44), *DFNB23* to *USH1F* (27, 42) and *USH2B* to *DFNB6* (29, 45).

With many of the Usher syndrome genes now identified, a more careful examination of the phenotype associated with mutations in any one gene is possible, providing some interesting observations. One mutation in the *USH2A* gene, Cys759Phe, accounts for at least 4.5% of recessive retinitis pigmentosa without hearing loss, and represents the single largest cause of non-syndromic blindness discovered to date among a sampling of 224 mostly unrelated North Ameri-

cans (46). Likewise, different mutations in the gene responsible for *USH1D* can be found to cause a phenotype similar to USH1, USH2, USH3 and recessive non-syndromic deafness (34, 47). Moreover, mutations in the gene responsible for *USH1B* are shown to cause USH1 or USH3-like symptoms, as well as dominant non-syndromic deafness (48, 49). We conclude from these studies that there are limitations to the current clinical classification of families inheriting Usher syndrome.

We can conclude from these clinical applications of molecular genetics to the study of Usher syndrome that many of the disease-causing genes are now identified, and that the more abundant mutant alleles are known. Much more study is needed to understand the pathophysiology of these genes so that at some future date therapy will be possible.

Cloned Usher loci and mouse models

USH1B/DFNB2/DFNA11 and *shaker 1*

USH1B was first localized among families from the United States enrolled for study at the Boys Town National Research Hospital (22, 23) and is the most common cause of USH1 in the United States (50) and Pakistan (unpublished data, SR, SR and ZMA). Subsequent to the initial mapping studies identifying *USH1B*, a large consanguineous Tunisian family segregating non-syndromic recessive deafness mapped to 11q14, was assigned the locus symbol *DFNB2* and hypothesized to be due to allelic mutations of the gene for *USH1B* (51). Recently, a detailed ophthalmological examination of affected individuals from the original *DFNB2* Tunisian family showed early signs of retinitis pigmentosa, suggesting that this family probably has an atypical Usher syndrome (52, 53). Moreover, a gene for dominantly inherited non-syndromic deafness segregating in a Japanese family was also mapped within the linkage region of *USH1B/DFNB2* (54) and is an allelic variant responsible for dominant non-syndromic locus 11 (*DFNA11*).

Homozygous shaker 1 (*sh1*) mice are deaf, and the defective gene maps to chromosome 7 (55), a region showing conserved synteny with homologs on human chromosome 11 harboring the gene for *USH1B/DFNB2/DFNA11* (22, 51, 54). The identification of unconventional myosin VIIa as the gene mutated in *sh1* (56) led quickly to the cloning of the human ortholog. As suspected, different mutant alleles of *MYO7A* cause *USH1B*, recessive, non-syndromic deafness *DFNB2* and dominant non-syndromic deafness *DFNA11* (30,

48, 57, 58). This later mutation is uniquely found in the coiled-coil domain responsible for dimerization of *MYO7A*, resulting in a dominant negative effect (48). A summary of *MYO7A* mutations identified in *USH1B*, *DFNB2*, and *DFNA11* subjects is shown in Table 2. These mutations are distributed across nearly all exons of *MYO7A*, but most are located in exons encoding the motor domain (59, 60). Unconventional myosins interact with actin through their motor domain and upon hydrolysis of ATP exert force to travel along actin filaments (61). *MYO7A* has 49 coding exons (62) and spans approximately 87 kb of genomic DNA on chromosome 11q14.1. The predicted human protein encoded by *MYO7A* is 2215 amino acids (Fig. 1) (63), and has 96% identity and 98% amino acid similarity with the mouse orthologue. A splice isoform, *MYO7b*, encoding only 1203 amino acids was also reported, but no functional studies on this shortened *MYO7A* have been reported (63). Additional details on the functional aspects of this protein are available elsewhere (64, 65).

USH1C/DFNB18

USH1C was mapped to chromosome 11p15.2-p14 (23) and subsequently refined to a 3-cM interval (24). Two groups reported the positional cloning of the *USH1C* gene encoding harmonin (31, 32). The structure of *USH1C* is complex with many alternatively spliced isoforms from 20 primary and eight alternative exons (32, 66).

Recently, we and others reported allelic variants of *USH1C* causing non-syndromic recessive deafness, designated *DFNB18* (44, 67, 68). Interestingly, the mutation 238-239insC, which was previously reported in six unrelated subjects of European or Pakistani ancestry inheriting *USH1C*, was found in two additional consanguineous Pakistani families and may be a common cause of *USH1C* in Pakistan (see Table 2) (67).

Harmonin has 94% identity and 95% amino acid similarity with mouse *Ush1C* isoform a1. In humans, harmonin has many tissue-specific isoforms (66). In the mouse inner ear, there are at least eight different alternatively spliced variants of harmonin (32). The predicted isoforms have two or three PDZ domains, one or two coiled-coil regions and, in some splice variants, a PST (proline, serine, threonine) domain (32). The harmonin b isoforms are found only in the inner ear, whereas the other isoforms have broader expression patterns (32). In the inner ear, harmonin is expressed in the organ of Corti as well as in the

five sensory areas of the vestibule (32). In the cochlea, harmonin isoform b expression is detected by E15 in differentiating hair cells at the basal turn of the cochlea and expression at the tips of the stereocilia can be seen as late as P30 (69). After P30, harmonin isoform b expression was undetectable, but the proteins encoded by other harmonin isoforms are found expressed in the cuticular plate and stereocilia throughout the post-natal life of the mice (69). A similar expression pattern is observed for vestibular hair cells (69).

PDZ domains are motifs that interact in a sequence-specific fashion with the C-terminal peptides or internal peptides that fold into a β -finger (see Fig. 1) (70). Typically, PDZ domains are 80–90 amino acids long and show some sequence divergence, which probably reflects diversity in binding specificity (70). The most general function of PDZ domains may be to localize specific ligands to the appropriate plasma membrane domain (71, 72).

Recently, two groups independently reported the interaction between harmonin PDZ domains, the second FERM and MyTh4 domains of myosin VIIa, and the cytoplasmic domain of cadherin 23 (69, 73). The first PDZ domain of harmonin interacts with myosin VIIa, while the second PDZ domain binds the cytoplasmic region of cadherin 23, and the third PDZ domain along with the PST domain might interact with F-actin. The interaction of all three proteins forms a transmembrane complex essential for the organization and stabilization of stereocilia (69, 73). The resulting complex along with cadherin 23 is found near the tip of the stereocilia, inferred from the misdirected transport of harmonin in myosin VIIa mutant mice (69).

USH1D/DFNB12 and *Waltzer (v)*

USH1D and *USH1F* map to human chromosome 10q in an interval that includes two non-syndromic recessive deafness loci, *DFNB12* and *DFNB23* (26, 27, 42, 43). The region of conserved synteny in the mouse includes three deafness mutants, *Waltzer (v)*, the modifier locus (*mdfw*) of deaf waddler (*dfw*) and the gene for age-related hearing loss (*Ahl*) (74–76). *Waltzer (v)* mice exhibit profound deafness with head tossing reflecting vestibular dysfunction. Ultrastructural analysis of the inner ears of *v* homozygous mice show normal inner and outer hair cell formation but the stereocilia are abnormal in number, organization, shape and position relative to the kinocilium (74).

Table 2. A summary of the published mutations causing Usher syndrome

Gene	Locus	Mutation	Domain	References
MYO7A	<i>DFNA11</i>	Δ886-888	Coiled coil	(48)
	<i>DFNB2</i>	R244P	Motor domain	(57)
		M599I	Motor domain	(58)
		IVS3-2	Motor domain	(57)
		IVS24-21	FERM domain	(98)
		1199insT	MyTH4	(57)
	<i>USH1B</i>	L16X	Motor domain	(98)
		G25R	Motor domain	(97)
		A26E	Motor domain	(99)
		C31X	Motor domain	(60)
		V67M	Motor domain	(99)
		75delG	Motor domain	(60)
		R90P	Motor domain	(99)
		120delC	Motor domain	(60)
		I134N	Motor domain	(99)
		R150X	Motor domain	(30)
		IVS5 + 1	Motor domain	(62)
		R212C	Motor domain	(30)
		R212H	Motor domain	(30)
		G214R	Motor domain	(62)
		ΔD218-I219	Motor domain	(30)
		A226T	Motor domain	(100)
		Q234X	Motor domain	(30)
		R241S	Motor domain	(98)
		R244P	Motor domain	(57)
		269delAAG	Motor domain	(99)
		R302H	Motor domain	(60)
		E314X	Motor domain	(60)
		Y333X	Motor domain	(60)
		A397D	Motor domain	(62)
		E450Q	Motor domain	(60)
		A457V	Motor domain	(99)
		468 + Q	Motor domain	(60)
		P503L	Motor domain	(60)
		G519D	Motor domain	(99)
		IVS13-1	Motor domain	(99)
		IVS13-8	Motor domain	(60)
		521delC	Motor domain	(97)
		532delA	Motor domain	(60)
		542insC	Motor domain	(99)
		C628X	Motor domain	(101)
		R634X	Motor domain	(101)
		R666X	Motor domain	(98)
		R669X	Motor domain	(101)
		724delC	Motor domain	(101)
		IVS18+1	Motor domain	(62)
		A826T	IQ motif	(62)
		G955S	Post coiled-coil domain	(102)
		E960X	Post-coiled-coil domain	(98)
		E968D	Post-coiled-coil domain	(99)
		E1080X	MyTH4 domain	(103)
		E1170K	MyTH4 domain	(103)
		IVS28 + 2	MyTH4 domain	(102)
		R1240E	MyTH4 domain	(98)
		R1240Q	MyTH4 domain	(99)
		IVS29 + 2	Post-MyTH4 domain	(101)
		A1288P	FERM domain	(98)
		R1343S	FERM domain	(98)
		1346delTTC	FERM domain	(99)
		R1602Q	FERM domain	(101)
		A1628S	SH3 domain	(101)
		Y1719C	Post-SH3 domain	(98)
		R1743W	MyTH4 domain	(99)
		Q1798X	MyTH4 domain	(98)
		L1858P	Post-MyTH4 domain	(99)
		R1861X	Post-MyTH4 domain	(62)

Table 2. Continued

		IVS40-2	Pre-FERM domain	(99)
		P1887L	FERM domain	(99)
		2018delG	FERM domain	(99)
		2065delC	FERM domain	(62)
		2119-2215del2 kb	FERM domain	(62)
		G2137E	FERM domain	(102)
		G2163S	FERM domain	(98)
		G2167D	FERM domain	(101)
	Atypical <i>USH1B</i>	L651P cpd. het. w/R1602Q	Motor domain and FERM domain	(49)
<i>USH1C</i>	<i>USH1C</i>	IVS1 + 1G > T	Amino terminus	(104)
		R31X	Amino terminus	(104)
		216G > A	Amino terminus	(31)
		238-239insC	Amino terminus	(31, 32, 104)
		IVS5 + 1G > A	PDZ1	(104)
		IVS5-2delA	PDZ1	(32)
		IVS8 + 2T > G	PDZ2	(67)
		769-770ins36	PDZ2	(67)
		G431V	Coiled coil	(68)
	<i>DFNB18</i>	P608R	PST	(68)
		R620L	PST	(68)
		R636C	PST	(68)
		IVS12 + 5G > C	PDZ2	(67)
<i>CDH23</i>	<i>DFNB12</i>	D124G	CA1	(47)
		N452S	CA4	(47)
		L480Q	CA5	(47)
		R582Q	CA6	(47)
		D990N	CA9	(34)
		R1060W	CA10	(47)
		G1186D	CA11	(47)
		D1341N	CA13	(105)
		A1586P	CA15	(47)
		E1595K	CA15	(47)
		D1846N	CA17	(47)
		D2045N	CA19	(34)
		D2148N	CA20	(47)
		D2202N	CA21	(34)
		R2465W	CA23	(47)
		R2608H	CA24	(47)
		I2950N	CA27	(34)
		R2956C	CA27	(34)
		P3059T	CA27-TM	(34)
	<i>USH1D</i>	Q58X	CA1	(47)
		1087delG	CA4	(47)
		A484P	CA5	(47)
		F995L	CA9	(47)
		P1206R	CA11	(47)
		3840insATGA	CA12	(47)
		Q1294X	CA12_	(34)
		Q1496H	CA14	(33)
		T1904T	CA18	(106)
		IVS45 + 1	CA19	(34)
		R2107X	CA20	(34)
		6933delT	CA21	(106)
		IVS51 + 5	CA23	(33)
		9626insC	CYT0	(47)
		T1209A	CA11/CA12_	(47)
		E2103X	CA20	(47)
		S2517G	CA23/CA24_	(47)
		E2624E	CA25	(47)
		R3175H	CYT0	(47)
	Atypical <i>USH1D</i>	193delC	CA1	(47)
		IVS4 + 1	CA1	(47)
		1112delT	CA4	(47)
		IVS20 + 1	CA7	(47)
		T1035T	CA10	(47)
		delM1281	CA12	(33)

Table 2. Continued

		R1502X	CA14	(47)
		R1746Q	CA16/CA17	(33)
		IVS45-9	CA19	(106)
		6155delC	CA19	(47)
		6968delC	CA22	(47)
		G2744S	CA26	(47)
		R2833G	CA26	(47)
		IVS66 + 1	CYTO	(34)
<i>PCDH15</i>	<i>USH1F</i>	R3X	Signal peptide	(35, 36)
		R245X	CA2	(111)
		1471delT	CA3	(36)
		IVS27-2A > G	CA11	(35)
<i>SANS</i>	<i>USH1G</i>	L48P	Ankyrin repeat 1	(37)
		186-187delCA	Ankyrin repeat 1	(37)
		393insG	Post 3rd Ankyrin repeat	(37)
		829-848del	Post 3rd Ankyrin repeat	(37)
<i>USH2A</i>	<i>USH2A</i>	R34X	Pre-laminin type VI	(107)
		R63X	Pre-laminin type VI	(107)
		238-239insCGTA	Pre-laminin type VI	(108)
		C163Y	Pre-laminin type VI	(107)
		V218E	Pre-laminin type VI	(109)
		V230M	Pre-laminin type VI	(107)
		L260X	Pre-laminin type VI	(85)
		921-922insCAGC	Laminin type VI domain	(85)
		C319Y	Laminin type VI domain	(85)
		R334W	Laminin type VI domain	(108)
		N346H	Laminin type VI domain	(85)
		W409X	Laminin type VI domain	(85)
		C419F	Laminin type VI domain	(85)
		C536R	1st laminin EGF-like	(107)
		L555V	1st laminin EGF-like	(109)
		1679delC	1st laminin EGF-like	(85)
		Q566X	1st laminin EGF-like	(85)
		R626X	2nd laminin EGF-like	(85)
		1965delT	3rd laminin EGF-like	(107)
		Q675X	3rd laminin EGF-like	(107)
		Q684Q	3rd laminin EGF-like	(85)
		G713R	4th laminin EGF-like	(107)
		2299delG	5th laminin EGF-like	(38)
		C847X	7th laminin EGF-like	(85)
		Q933X	8th laminin EGF-like	(107)
		2878delAA	9th laminin EGF-like	(107)
		2898delG	9th laminin EGF-like	(38)
		3840-41GA→CT	3rd Fibronectin type III	(85)
		R1295X	3rd Fibronectin type III	(85)
		4338-9delCT	4th Fibronectin type III	(38)
		4510-4511insA	Carboxy tail region	(85)
		T1515M	Carboxy tail region	(108)
	RP without HL	C759F	5th laminin EGF-like	(46)
<i>USH3A</i>	<i>USH3A</i>	N48K	Pre-1st TM	(40, 41)
		149delCAGG/ insTGTC-CAAT	Pre-1st TM	(41)
		165delC	Pre-1st TM	(41)
		187-209del23bp	Pre-1st TM	(40)
		Y63X	Pre-1st TM	(40)
		M120K	1st TM	(39, 41)
		L150P	2nd TM	(41)
		459-461delATT	2nd TM	(39, 41)
		Y100X	2nd TM	(39, 41)

Atypical cases of Usher syndrome are to draw attention to mutations that do not fit the typical Usher phenotype associated with mutations found in a particular gene. In some instances, it is used synonymously with the USH3 phenotype. The following abbreviations are used in this table: FERIM: a homology shared among the 4.1, ezrin, radixin and moesin proteins; MyTH4: a myosin tail homology 4 domain found among myosins and kinesins; IQ motif: calmodulin-binding motif containing isoleucine and glutamine residues; SH3: first described in the Src tyrosine kinase, a domain involved in binding to other proteins through proline and hydrophobic amino acids; PDZ: a protein domain first identified by homologies in PSD-95, Dlg and ZO-1/2, that can bind to specific sequences in other proteins; CA: a domain found among cadherins, these extracellular repeats are involved in Ca^{2+} mediated cell-cell adhesion; CYTO: refers to a cytoplasmic region of a transmembrane protein; TM: refers to the transmembrane domain of a protein; RP: refers to retinitis pigmentosa; HL: refers to hearing loss. Please see <http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml> for additional domain information regarding these and other protein domains.




Fig. 1. Schematic representation of the predicted structure of Myosin VIIa with a motor head region which contains binding sites for ATP and actin followed by a neck region containing five isoleucine-glutamine (IQ) motifs (yellow). The tail region consists of one coiled-coil region (CC), two myosin tail homology four domains (MyTH4), one SH3 domain and two FERM domains. Also shown is a schematic representation of the predicted structure of harmonin isoform b with three PDZ domains, a CC domain (for self-multimerization) and a PST region (proline, serine and threonine rich region that might interact with an SH3 domain of a yet unknown protein). In addition, there is schematic representation of the predicted structure of SANS with 3 ankyrin repeats (these repeats associate to form higher order structures) and a SAM domain (found in signaling and nuclear proteins and appears to mediate cell-cell initiated signal transduction via the binding of SH2-containing proteins and in many cases mediates homodimerization, see the conserved domain data base at NCBI, <http://www.ncbi.nlm.nih.gov/>). Also shown is the predicted structure of cadherin 23 comprising 27 cadherin repeats which are involved in Ca^{2+} -dependent cell adhesion, one transmembrane domain and a cytoplasmic tail with no homology to any known intracellular functional domain. Cadherin 23 is thought to interact with the PDZ-2 domain of harmonin isoform b in the stereocilia (37, 73).

USH1D, *DFNB12* subjects and the waltzer mice have mutations in the gene encoding cadherin 23 (33, 34, 74). A summary of the known mutations of *CDH23*, identified in *USH1D* and *DFNB12* subjects, is given in Table 2. It can be seen that missense mutations, presumed hypomorphs, of *CDH23* cause non-syndromic recessive deafness while more severe mutant alleles (nonsense or truncating mutations) are associated with *USH1D* (34, 47). Some compound heterozygotes with one severe *CDH23* allele and a hypomorphic allele of *CDH23* have an Usher phenotype (47). No allelic variants of *CDH23* are reported which cause retinitis pigmentosa in individuals with normal hearing. No mutant alleles of mouse *Cdh23* are associated with age-related hearing loss or the modifier-of-deaf waddler, although the fine genetic mapping of *Cdh23^v* and *mdfw* supports

the possibility that these loci are caused by allelic mutations (77).

CDH23 encodes a protein with 3354 amino acids that has 94% identity and 97% amino acid similarity with mouse cadherin 23. Cadherin 23 is predicted to have 27 ectodomains (or cadherin repeats which are involved in Ca^{2+} -dependent cell adhesion), a signal peptide at the amino terminus, one transmembrane domain and a unique cytoplasmic carboxy terminal tail (Fig. 1) (34, 74). Cadherins belong to a superfamily of glycosylated proteins typically mediating cell-cell adhesion via calcium-dependent interactions through homophilic ectodomains (78). In the inner ear, cadherin 23 is present along the entire developing stereocilia. Eventually its expression is restricted to the tip of the stereocilia (69). Cadherin 23 is found in the photoreceptor layer of developmental

stage P0 in mice (73) and presumably is essential for stereocilia formation (69, 73).

USH1F/DFNB23 and *Ames Waltzer* (*av*)

USH1F was mapped to chromosome 10q21-22, in a 15-cM interval centromeric to *DFNB12/USH1D* (27). *DFNB23*, an autosomal non-syndromic recessive deafness locus, maps to an interval overlapping *USH1F* (42). In the United States, *USH1D* and *USH1F* mutations combined are the second most common cause of Usher syndrome (50). Our data from Pakistani families supports this assessment (34, 35, 47, 67, see Table 1).

The mouse *Ames waltzer* (*av*) phenotype is due to a recessive mutation in *Pcdh15* and is the mouse model for *USH1F*. Homozygote *Pcdh15* mutant mice are deaf with a degeneration of the inner ear neuroepithelium and vestibular dysfunction (79). *PCDH15* is the human ortholog and was proposed as a candidate for *USH1F* (79). Three different mutant alleles of *PCDH15* from four families segregating *USH1F* (35, 36)

were recently reported. Protocadherin 15 has 11 ectodomains (cadherin repeats which are involved in Ca^{2+} -dependent cell adhesion), at least one transmembrane domain, a unique cytoplasmic carboxy domain (Fig. 2), and display 83% amino acid identity and 88% similarity with murine *Pcdh15* (35). It is widely expressed in inner and outer hair cells and in many other tissues from early development through adulthood (80). It is as yet unknown whether *Pcdh15* is part of the same complex of proteins found interacting in the stereocilia of hair cells, but it does contain a class 1 PDZ interacting consensus sequence at the carboxy end.

In an ultrastructural analysis, the stereocilia degenerate and are disorganized, and for some alleles the stereocilia bundles were rotated 90° from their normal position (81). The endocochlear potential is normal in homozygous *Ames waltzer* (*av^J* and *av^{2J}*), excluding the involvement of the stria vascularis in the primary pathology (81). Protocadherin 15 is the second cadherin-like gene reported to cause deafness when mutated.




Fig. 2. (a) The domains of protocadherin 15 (PCDH15) predicted from 1955 amino acids. Protocadherin 15 has a signal peptide at the amino terminus, 11 extracellular calcium-binding domains, one predicted transmembrane domain and a unique carboxy terminus. TMPred and SMART predicted two transmembrane domains (1054–1072, and 1376–1397), TMHMM predicted only one transmembrane domain at 1376–1397 (35). (b) The predicted structure of usherin encoded by *USH2A*. There is a signal peptide followed by 285 amino acids of uncharacterized amino acid sequence, a laminin domain VI-like motif, 10 laminin type EGF-like modules, four fibronectin-like type III repeats and a unique carboxy terminus (38). (c) Schematic representation of clarin 1, recently identified by two different research groups, predicted to have three or possibly four transmembrane domains with different amino and carboxy termini from the previously identified isoform (40, 41).

USH1G and Jackson shaker (js)

USH1G maps to a 23-cM interval on chromosome 17q24-25 and was found segregating in a Palestinian family from Jordan (28). The mouse mutant Jackson shaker (*js*) (82) is linked to the syntenic region of mouse chromosome 11. Two different BACs, both containing *Sans* (scaffold protein containing ankyrin repeats and SAM domain, Fig. 1) found on the 72-kbp overlap in common between them, rescue the *js* phenotype. The two known *js* alleles harbor mutations in this gene (82) and four different mutant alleles of *SANS* were found segregating in *USH1G* linked families, confirming that *js* is the mouse homolog to *USH1G* (37). *Sans* protein is predicted to contain ankyrin repeats and a SAM domain. Both domains are known to mediate protein-protein interactions, hence the name scaffolding protein. *Sans* protein is also predicted to have a class-I PDZ-interacting consensus sequence and co-localizes with harmonin (a protein with several PDZ domains, see Fig. 1) upon co-transfection in HeLa cells (37), evidence that *Sans* could be part of the same molecular complex containing harmonin, myosin VIIa and caderin 23.

USH2A

USH2A was the first Usher syndrome locus to be identified (20). Subsequent analysis of additional *USH2* families refined the linkage region to 1 Mb (83). Recent studies revealed that *USH2* is the most common form of Usher syndrome and may account for more than 50% of all Usher subjects in some populations (9, 38). Moreover, *USH2A* could be responsible for as much as 85% of *USH2* cases (84).

In 1998, a defect of the gene encoding a novel protein, Usherin, proved responsible for the *USH2A* phenotype (38). Usherin has 1546 amino acids (170–180 kDa) with 70% identity and 81% amino acid similarity with mouse usherin and the predicted protein structure has four main structural motifs (85). A predicted signal peptide (see Fig. 2) is followed by thrombospondin domain (Ts), laminin N-terminal domain (domain VI, LN), 10 laminin-type epidermal growth factor-like domains (LE) and four fibronectin type 3 domains (85). Usherin is a critical element of the basement membrane in the cochlea and retina, but is also expressed in many other tissues (86).

Mutational screening of *USH2A* subjects revealed 2299delG as a common and widespread mutation found in subjects from Europe, the United States, South Africa and China (85, 87, 88).

Families with this mutation are described as either *USH2* with moderate-to-severe hearing loss and normal vestibular function, or as atypical Usher families (similar to *USH3*) with progressive hearing loss and vestibular dysfunction (88). The frequency of this mutation in *USH2A* patients is high enough (approximately 20%) that it may be the single highest cause of retinitis pigmentosa in the human population (85), vying with Cys759Phe of the same gene causing as much as 4.5% of recessive retinitis pigmentosa without hearing loss (46). Since the initial identification of *USH2A*, more than 32 allelic variants have been reported (see Table 2).

USH3A

USH3A is common in eastern Finland and accounts for approximately 40% of Usher patients in that country (39). The chromosomal location of *USH3A* on chromosome 3q23-24 was determined from a genome-wide mapping effort on Finnish *USH3A* families (18). Linkage disequilibrium refined the location of the Finnish *USH3A* mutation to an interval of approximately 1 cM between markers D3S1299 and D3S3625 (89) and later to a genomic interval of only 250 kb (90). *USH3A* mutant alleles are not limited to Finland (84, 91–93).

Shotgun sequencing of two overlapping BACs in the *USH3A* linkage interval helped in the identification of a novel gene, *USH3A* (39). Mutations were found in *USH3A*, initially thought to have only four exons with an alternatively spliced first exon. Sequence analysis revealed the expected founder mutation (Y100X, or Fin_{major}) in the majority of the Finnish *USH3A* families (39). One other Finnish *USH3A* mutant allele is c.131T→A transversion at codon 44 in exon 2, resulting in M44K (Fin_{minor}, see Table 2) (39). Recently, two groups independently identified additional isoforms of *USH3A* using different strategies (40, 41). The longest identified transcript of *USH3A* has an exon upstream of the previously reported first exon along with exons 3 and 4, including the intervening intron between exons 3 and 4 (40, 41).

USH3A encodes the protein clarin-1 (see Fig. 2) with 232 amino acids and three or possibly four predicted transmembrane domains (40, 41). In mice, three different tissue-specific alternatively spliced isoforms of *Ush3A* were identified (40). The role of this gene in the cochlea and retina is yet to be determined, though it is postulated to participate in the synapse junctions between hair cells and cochlear ganglion cells because of a

weak similarity to stargazin (40). Additional human *USH3A* paralogs encoding clarin 2 and clarin 3 have been identified, located on chromosome 4p15.3 and 10q26.2, respectively. It is currently not known in what tissues these genes are expressed. They have more than 50% amino acid similarity with *USH3A* (clarin 1), and like *USH3A* contain three putative transmembrane domains (40).

Conclusion

Usher syndrome is by far the most common form of inherited deafness found in combination with retinitis pigmentosa. It is a heterogeneous disorder both clinically and genetically. Based on clinical phenotypes, Usher syndrome is classified into three main types, USH1, USH2 and USH3. USH1 is the most genetically heterogeneous with at least eight different loci. There are four loci for USH2 and at least two loci for USH3 (64). Of the 11 published loci, genes for seven have been identified as, *MYO7A*, *USH1C*, *CDH23*, *PCDH15*, *SANS*, *USH2A* and *USH3A* encoding unconventional myosin VIIa, harmonin, cadherin 23, protocadherin 15, SANS, usherin and clarin 1, respectively. Five of these seven genes are expressed in the outer and inner hair cells of the organ of Corti while Usherin is known to be part of the extracellular basement membrane matrix and clarin-1 is expressed in the external sulcus, matrix of the limbus and spiral ligament (94).

Interactions between four USH1 proteins (myosin VIIa, harmonin b, SANS and cadherin 23) were recently demonstrated. The transmembrane complex formed by their interactions ensures the integrity of the stereocilia (69, 73). It would be interesting to determine the role, if any, that Pcdh15 has in this complex or in a similar complex as the hair cell phenotype of Pcdh15 mutants is very similar to cadherin 23, myosin VIIa and Sans mutant mice.

The most devastating aspect of Usher syndrome is progressive retinopathy. Interestingly, murine models of *USH1B*, *USH1D*, *USH1F* and now *USH1G* are reportedly deaf with vestibular hypofunction but they have no observed retinal degeneration (64). These mouse models are excellent for the study of hearing loss but not the pathophysiology of retinitis pigmentosa. The lack of a significant retinal phenotype in homozygous shaker 1, waltzer, Ames waltzer and Jackson shaker mice may indicate that these genes play different functions in the retina of mice as compared with humans, or perhaps there is compensation by a

modifier gene in these strains that suppresses the retinal phenotype. Alternatively, in the mouse retina there may be functional redundancy by one of the other protein family members that can substitute for the absence of Myo7a, Cdh23, Pcdh15 or SANS. On the other hand, the absence of retinitis pigmentosa may provide models for the study of a redundant function in the mouse that permits retention of normal retinal function and, once defined, might be activated as therapy or prevention of retinitis pigmentosa in humans.

Acknowledgements

We would like to thank Drs Susan Sullivan, Robert Morell and Thomas Friedman for many helpful comments to improve this manuscript.

References

1. Admiraal RJ, Huygen PL. Changes in the aetiology of hearing impairment in deaf-blind pupils and deaf infant pupils at an institute for the deaf. *Int J Pediatr Otorhinolaryngol* 2000; 55: 133–142.
2. Armitage IM, Burke JP, Buffin JT. Visual impairment in severe and profound sensorineural deafness. *Arch Dis Child* 1995; 73: 53–56.
3. Nicoll AM, House P. Ocular abnormalities in deaf children. a discussion of deafness and retinal pigment changes. *Aust N Z J Ophthalmol* 1988; 16: 205–208.
4. VonGraefe A. Exceptionelles Verhalten des Gesichtsfeldes bei Pigmententartung der Netzhaut. *Archiv für Ophthalmologie* 1858; 4: 250–253.
5. Kloepper HW, Laguaite JK. The hereditary syndrome of congenital deafness and retinitis pigmentosa. (Usher's syndrome). *Laryngoscope* 1966; 76: 850–862.
6. Rosenberg T, Haim M, Hauch AM et al. The prevalence of Usher syndrome and other retinal dystrophy-hearing impairment associations. *Clin Genet* 1997; 51: 314–321.
7. Boughman JA, Vernon M, Shaver KA. Usher syndrome: definition and estimate of prevalence from two high-risk populations. *J Chronic Dis* 1983; 36: 595–603.
8. Haim M. Prevalence of retinitis pigmentosa and allied disorders in Denmark. II. Systemic involvement and age at onset. *Acta Ophthalmol (Copenh)* 1992; 70: 417–426.
9. Hope CI, Bunday S, Proops D et al. Usher syndrome in the city of Birmingham – prevalence and clinical classification. *Br J Ophthalmol* 1997; 81: 46–53.
10. Boughman JA, Conneally PM, Nance WE. Population genetic studies of retinitis pigmentosa. *Am J Hum Genet* 1980; 32: 223–235.
11. Haim M. Epidemiology of retinitis pigmentosa in Denmark. *Acta Ophthalmol Scand* 2002; 80 (Suppl. 233): 1–34.
12. Fortnum HM, Summerfield AQ, Marshall DH et al. Prevalence of permanent childhood hearing impairment in the United Kingdom and implications for universal neonatal hearing screening: questionnaire based ascertainment study. *BMJ* 2001; 323: 536–540.
13. Fortnum HM, Marshall DH, Summerfield AQ. Epidemiology of the UK population of hearing-impaired children, including characteristics of those with and without cochlear implants – audiology, aetiology, comorbidity and affluence. *Int J Audiol* 2002; 41: 170–179.

14. Marazita ML, Ploughman LM, Rawlings B et al. Genetic epidemiological studies of early-onset deafness in the U.S. school-age population. *Am J Med Genet* 1993; 46: 486–491.
15. Smith RJ, Berlin CI, Hejtmancik JF et al. Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. *Am J Med Genet* 1994; 50: 32–38.
16. Tsilou ET, Rubin BI, Caruso RC et al. Usher syndrome clinical types I and II: could ocular symptoms and signs differentiate between the two types? *Acta Ophthalmol Scand* 2002; 80: 196–201.
17. Wagenaar M, van Aarem A, Huygen P et al. Hearing impairment related to age in Usher syndrome types 1B and 2A. *Arch Otolaryngol Head Neck Surg* 1999; 125: 441–445.
18. Sankila EM, Pakarinen L, Kaariainen H et al. Assignment of an Usher syndrome type III (USH3) gene to chromosome 3q. *Hum Mol Genet* 1995; 4: 93–98.
19. Otterstedde CR, Spandau U, Blankenagel A et al. A new clinical classification for Usher's syndrome based on a new subtype of Usher's syndrome type I. *Laryngoscope* 2001; 111: 84–86.
20. Kimberling WJ, Weston MD, Moller C et al. Localization of Usher syndrome type II to chromosome 1q. *Genomics* 1990; 7: 245–249.
21. Lewis RA, Otterud B, Stauffer D et al. Mapping recessive ophthalmic diseases: linkage of the locus for Usher syndrome type II to a DNA marker on chromosome 1q. *Genomics* 1990; 7: 250–256.
22. Kimberling WJ, Moller CG, Davenport S et al. Linkage of Usher syndrome type I gene (USH1B) to the long arm of chromosome 11. *Genomics* 1992; 14: 988–994.
23. Smith RJ, Lee EC, Kimberling WJ et al. Localization of two genes for Usher syndrome type I to chromosome 11. *Genomics* 1992; 14: 995–1002.
24. Keats BJ, Nouri N, Pelias MZ et al. Tightly linked flanking microsatellite markers for the Usher syndrome type I locus on the short arm of chromosome 11. *Am J Hum Genet* 1994; 54: 681–686.
25. Friedman T, Battey J, Kachar B et al. Modifier genes of hereditary hearing loss. *Curr Opin Neurobiol* 2000; 10: 487–493.
26. Wayne S, Der Kaloustian VM, Schloss M et al. Localization of the Usher syndrome type ID gene (USH1D) to chromosome 10. *Hum Mol Genet* 1996; 5: 1689–1692.
27. Wayne S, Lowry RB, McLeod DR et al. Localization of the Usher syndrome type IF (USH1F) to chromosome 10. *Am J Hum Genet* 1997; 61: (Abstract) 1752.
28. Mustapha M, Chouery E, Torchard-Pagnez D et al. A novel locus for Usher syndrome type I, USH1G, maps to chromosome 17q24-25. *Hum Genet* 2002; 110: 348–350.
29. Hmani M, Ghorbel A, Boulila-Elgaied A et al. A novel locus for Usher syndrome type II, USH2B, maps to chromosome 3 at p23-24.2. *Eur J Hum Genet* 1999; 7: 363–367.
30. Weil D, Blanchard S, Kaplan J et al. Defective myosin VIIA gene responsible for Usher syndrome type 1B. *Nature* 1995; 374: 60–61.
31. Bitner-Glindzicz M, Lindley KJ, Rutland P et al. A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene. *Nat Genet* 2000; 26: 56–60.
32. Verpy E, Leibovici M, Zwaenepoel I et al. A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C. *Nat Genet* 2000; 26: 51–55.
33. Bolz H, von Brederlow B, Ramirez A et al. Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D. *Nat Genet* 2001; 27: 108–112.
34. Bork JM, Peters LM, Riazuddin S et al. Usher syndrome 1D and nonsyndromic autosomal recessive deafness DFNB12 are caused by allelic mutations of the novel cadherin-like gene CDH23. *Am J Hum Genet* 2001; 68: 26–37.
35. Ahmed ZM, Riazuddin S, Bernstein SL et al. Mutations of the protocadherin gene PCDH15 cause Usher syndrome type 1F. *Am J Hum Genet* 2001; 69: 25–34.
36. Alagramam KN, Yuan H, Kuehn MH et al. Mutations in the novel protocadherin PCDH15 cause Usher syndrome type 1F. *Hum Mol Genet* 2001; 10: 1709–1718.
37. Weil D, El-Amraoui A, Masmoudi S et al. Usher syndrome type I G (USH1G) is caused by mutations in the gene encoding SANS, a protein that associates with the USH1C protein, harmonin. *Hum Mol Genet* 2003; 12: 463–471.
38. Eudy JD, Weston MD, Yao S et al. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. *Science* 1998; 280: 1753–1757.
39. Joensuu T, Hamalainen R, Yuan B et al. Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3. *Am J Hum Genet* 2001; 69: 673–684.
40. Adato A, Vreugde S, Joensuu T et al. USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses. *Eur J Hum Genet* 2002; 10: 339–350.
41. Fields RR, Zhou G, Huang D et al. Usher syndrome type III. revised genomic structure of the USH3 gene and identification of novel mutations. *Am J Hum Genet* 2002; 71: 607–617.
42. Hereditary Hearing Loss Homepage. <http://dnalab-www.uia.ac.be/dnalab/hhh/>.
43. Chaib H, Place C, Salem N et al. Mapping of DFNB12, a gene for a non-syndromal autosomal recessive deafness, to chromosome 10q21-22. *Hum Mol Genet* 1996; 5: 1061–1064.
44. Jain PK, Lalwani AK, Li XC et al. A gene for recessive nonsyndromic sensorineural deafness (DFNB18) maps to the chromosomal region 11p14-p15.1 containing the Usher syndrome type 1C gene. *Genomics* 1998; 50: 290–292.
45. Fukushima K, Ramesh A, Srisailapathy CR et al. An autosomal recessive nonsyndromic form of sensorineural hearing loss maps to 3p-DFNB6. *Genome Res* 1995; 5: 305–308.
46. Rivolta C, Sweklo EA, Berson EL et al. Missense mutation in the USH2A gene: association with recessive retinitis pigmentosa without hearing loss. *Am J Hum Genet* 2000; 66: 1975–1978.
47. Astuto LM, Bork JM, Weston MD et al. CDH23 mutation and phenotype heterogeneity: a profile of 107 diverse families with Usher syndrome and nonsyndromic deafness. *Am J Hum Genet* 2002; 71: 262–275.
48. Liu XZ, Walsh J, Tamagawa Y et al. Autosomal dominant non-syndromic deafness caused by a mutation in the myosin VIIA gene. *Nat Genet* 1997; 17: 268–269.
49. Liu XZ, Hope C, Walsh J et al. Mutations in the myosin VIIA gene cause a wide phenotypic spectrum, including atypical Usher syndrome. *Am J Hum Genet* 1998; 63: 909–912.
50. Astuto LM, Weston MD, Carney CA et al. Genetic heterogeneity of Usher syndrome: analysis of 151 families with Usher type I. *Am J Hum Genet* 2000; 67: 1569–1574.
51. Guilford P, Ayadi H, Blanchard S et al. A human gene responsible for neurosensory, non-syndromic recessive deafness is a candidate homologue of the mouse sh-1 gene. *Hum Mol Genet* 1994; 3: 989–993.

52. Zina ZB, Masmoudi S, Ayadi H et al. From DFNB2 to Usher syndrome: variable expressivity of the same disease. *Am J Med Genet* 2001; 101: 181–183.
53. Astuto LM, Kelley PM, Askew JW et al. Searching for evidence of DFNB2. *Am J Med Genet* 2002; 109: 291–297.
54. Tamagawa Y, Kitamura K, Ishida T et al. A gene for a dominant form of non-syndromic sensorineural deafness (DFNA11) maps within the region containing the DFNB2 recessive deafness gene. *Hum Mol Genet* 1996; 5: 849–852.
55. Brown SD, Brown KA, Sutcliffe MJ et al. Reverse genetic approaches to cloning deafness genes. *Ann N Y Acad Sci* 1991; 630: 93–99.
56. Gibson F, Walsh J, Mburu P et al. A type VII myosin encoded by the mouse deafness gene shaker-1. *Nature* 1995; 374: 62–64.
57. Liu XZ, Walsh J, Mburu P et al. Mutations in the myosin VIIA gene cause non-syndromic recessive deafness. *Nat Genet* 1997; 16: 188–190.
58. Weil D, Kussel P, Blanchard S et al. The autosomal recessive isolated deafness, DFNB2, and the Usher 1B syndrome are allelic defects of the myosin-VIIA gene. *Nat Genet* 1997; 16: 191–193.
59. Friedman TB, Sellers JR, Avraham KB. Unconventional myosins and the genetics of hearing loss. *Am J Med Genet* 1999; 89: 147–157.
60. Weston MD, Kelley PM, Overbeck LD et al. Myosin VIIA mutation screening in 189 Usher syndrome type I patients. *Am J Hum Genet* 1996; 59: 1074–1083.
61. Mermall V, Post PL, Mooseker MS. Unconventional myosins in cell movement, membrane traffic, and signal transduction. *Science* 1998; 279: 527–533.
62. Adato A, Weil D, Kalinski H et al. Mutation profile of all 49 exons of the human myosin VIIA gene, and haplotype analysis, in Usher 1B families from diverse origins. *Am J Hum Genet* 1997; 61: 813–821.
63. Chen ZY, Hasson T, Kelley PM et al. Molecular cloning and domain structure of human myosin-VIIa, the gene product defective in Usher syndrome 1B. *Genomics* 1996; 36: 440–448.
64. Petit C. Usher syndrome: from genetics to pathogenesis. *Annu Rev Genomics Hum Genet* 2001; 2: 271–297.
65. Libby RT, Steel KP. The roles of unconventional myosins in hearing and deafness. *Essays Biochem* 2000; 35: 159–174.
66. Scanlan MJ, Williamson B, Jungbluth A et al. Isoforms of the human PDZ-73 protein exhibit differential tissue expression. *Biochim Biophys Acta* 1999; 1445: 39–52.
67. Ahmed ZM, Smith TN, Riazuddin S et al. Nonsyndromic recessive deafness *DFNB18* and Usher syndrome type IC are allelic mutations of *USH1C*. *Hum Genet* 2002; 110: 527–531.
68. Ouyang XM, Xia XJ, Verpy E et al. Mutations in the alternatively spliced exons of *USH1C* cause non-syndromic recessive deafness. *Hum Genet* 2002; 111: 26–30.
69. Boeda B, El-Amraoui A, Bahloul A et al. Myosin VIIa, harmonin and cadherin 23, three Usher I gene products that cooperate to shape the sensory hair cell bundle. *EMBO J* 2002; 21: 6689–6699.
70. Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. *Annu Rev Neurosci* 2001; 24: 1–29.
71. Fanning AS, Anderson JM. Protein modules as organizers of membrane structure. *Curr Opin Cell Biol* 1999; 11: 432–439.
72. Fanning AS, Anderson JM. PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. *J Clin Invest* 1999; 103: 767–772.
73. Siemens J, Kazmierczak P, Reynolds A et al. The Usher syndrome proteins cadherin 23 and harmonin form a complex by means of PDZ-domain interactions. *Proc Natl Acad Sci USA* 2002; 99: 14946–14951.
74. Di Palma F, Holme RH, Bryda EC et al. Mutations in *Cdh23*, encoding a new type of cadherin, cause stereocilia disorganization in waltzer, the mouse model for Usher syndrome type 1D. *Nat Genet* 2001; 27: 103–107.
75. Johnson KR, Erway LC, Cook SA et al. A major gene affecting age-related hearing loss in C57BL/6J mice. *Hear Res* 1997; 114: 83–92.
76. Noben-Trauth K, Zheng QY, Johnson KR et al. *mdfw*: a deafness susceptibility locus that interacts with deaf waddler (*dfw*). *Genomics* 1997; 44: 266–272.
77. Bryda EC, Kim HJ, Legare ME et al. High-resolution genetic and physical mapping of modifier-of-deafwaddler (*mdfw*) and Waltzer (*Cdh23v*). *Genomics* 2001; 73: 338–342.
78. Boggon TJ, Murray J, Chappuis-Flament S et al. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. *Science* 2002; 296: 1308–1313.
79. Alagramam KN, Murcia CL, Kwon HY et al. The mouse Ames waltzer hearing-loss mutant is caused by mutation of *Pcdh15*, a novel protocadherin gene. *Nat Genet* 2001; 27: 99–102.
80. Murcia CL, Woychik RP. Expression of *Pcdh15* in the inner ear, nervous system and various epithelia of the developing embryo. *Mech Dev* 2001; 105: 163–166.
81. Raphael Y, Kobayashi KN, Dootz GA et al. Severe vestibular and auditory impairment in three alleles of Ames waltzer (*av*) mice. *Hear Res* 2001; 151: 237–249.
82. Kikkawa Y, Shitara H, Wakana S et al. Mutations in a new scaffold protein *Sans* cause deafness in Jackson shaker mice. *Hum Mol Genet* 2003; 12: 453–461.
83. Sumegi J, Wang JY, Zhen DK et al. The construction of a yeast artificial chromosome (YAC) contig in the vicinity of the Usher syndrome type IIa (*USH2A*) gene in 1q41. *Genomics* 1996; 35: 79–86.
84. Kimberling WJ, Weston MD, Moller C et al. Gene mapping of Usher syndrome type IIa: localization of the gene to a 2.1-cM segment on chromosome 1q41. *Am J Hum Genet* 1995; 56: 216–223.
85. Weston MD, Eudy JD, Fujita S et al. Genomic structure and identification of novel mutations in *usherin*, the gene responsible for Usher syndrome type IIa. *Am J Hum Genet* 2000; 66: 1199–1210.
86. Bhattacharya G, Miller C, Kimberling WJ et al. Localization and expression of *usherin*: a novel basement membrane protein defective in people with Usher's syndrome type IIa. *Hear Res* 2002; 163: 1–11.
87. Dreyer B, Tranebjaerg L, Brox V et al. A common ancestral origin of the frequent and widespread 2299delG *USH2A* mutation. *Am J Hum Genet* 2001; 69: 228–234.
88. Liu XZ, Hope C, Liang CY et al. A mutation (2314delG) in the Usher syndrome type IIA gene: high prevalence and phenotypic variation. *Am J Hum Genet* 1999; 64: 1221–1225.
89. Joensuu T, Blanco G, Pakarinen L et al. Refined mapping of the Usher syndrome type III locus on chromosome 3, exclusion of candidate genes, and identification of the putative mouse homologous region. *Genomics* 1996; 38: 255–263.
90. Joensuu T, Hamalainen R, Lehesjoki AE et al. A sequence-ready map of the Usher syndrome type III critical region on chromosome 3q. *Genomics* 2000; 63: 409–416.
91. Adato A, Kalinski H, Weil D et al. Possible interaction between *USH1B* and *USH3* gene products as implied by

- apparent digenic deafness inheritance. *Am J Hum Genet* 1999; 65: 261–265.
92. Espinos C, Millan JM. Investigacion genetica sobre el sindrome de Usher en Espana. [Genetic research on Usher's syndrome in Spain]. *Med Clin (Barc)* 1998; 110: 340–341.
93. Gasparini P, De Fazio A, Croce AI et al. Usher syndrome type III (USH3) linked to chromosome 3q in an Italian family. *J Med Genet* 1998; 35: 666–667.
94. Fields RR, Kimberling WJ, Cosgrove DE. Localization and developmental expression of the protein encoded for by the Usher syndrome III gene. *Assoc Res Otolaryngol* 2003; (abstract) 1047, <http://www.aro.org/>.
95. Kaplan J, Gerber S, Bonneau D et al. A gene for Usher syndrome type I (USH1A) maps to chromosome 14q. *Genomics* 1992; 14: 979–987.
96. Chaib H, Kaplan J, Gerber S et al. A newly identified locus for Usher syndrome type I, USH1E, maps to chromosome 21q21. *Hum Mol Genet* 1997; 6: 27–31.
97. Liu XZ, Newton VE, Steel KP et al. Identification of a new mutation of the myosin VII head region in Usher syndrome type I. *Hum Mutat* 1997; 10: 168–170.
98. Janecke AR, Meins M, Sadeghi M et al. Twelve novel myosin VIIA mutations in 34 patients with Usher syndrome type I. confirmation of genetic heterogeneity. *Hum Mutat* 1999; 13: 133–140.
99. Bharadwaj AK, Kasztejna JP, Huq S et al. Evaluation of the myosin VIIA gene and visual function in patients with Usher syndrome type I. *Exp Eye Res* 2000; 71: 173–181.
100. Mena A, Camara J, Vieira H et al. New mutations in myosin VIIa gene in the Portuguese population. *Am J Hum Genet* 2000; 67 (4, Suppl.): (abstract) 2263.
101. Weston MD, Carney CA, Rivedal SA et al. Spectrum of myosin VIIA mutations causing Usher syndrome type 1b. *Assoc Res Otolaryngol* 1998; (abstract) 181, <http://www.aro.org/>.
102. Levy G, Levi-Acobas F, Blanchard S et al. Myosin VIIA gene: heterogeneity of the mutations responsible for Usher syndrome type IB. *Hum Mol Genet* 1997; 6: 111–116.
103. Cuevas JM, Espin SC, Millan JM et al. Identification of three novel mutations in the MYO7A gene. *Hum Mutat* 1999; 14: 181.
104. Zwaenepoel I, Verpy E, Blanchard S et al. Identification of three novel mutations in the USH1C gene and detection of thirty-one polymorphisms used for haplotype analysis. *Hum Mutat* 2001; 17: 34–41.
105. de Brouwer AP, Pennings RJ, Roeters M et al. Mutations in the calcium-binding motifs of CDH23 and the 35delG mutation in GJB2 cause hearing loss in one family. *Hum Genet* 2003; 112: 156–163.
106. von Brederlow B, Bolz H, Janecke A et al. Identification and in vitro expression of novel CDH23 mutations of patients with Usher syndrome type 1D. *Hum Mutat* 2002; 19: 268–273.
107. Dreyer B, Tranebjaerg L, Rosenberg T et al. Identification of novel USH2A mutations: implications for the structure of USH2A protein. *Eur J Hum Genet* 2000; 8: 500–506.
108. Adato A, Weston MD, Berry A et al. Three novel mutations and twelve polymorphisms identified in the USH2A gene in Israeli USH2 families. *Hum Mutat* 2000; 15: 388.
109. Leroy BP, Aragon-Martin JA, Weston MD et al. Spectrum of mutations in USU2A in British patients with Usher syndrome type II. *Exp Eye Res* 2001; 72: 503–509.
110. Picke-Dahl S, Moller CG, Kelley PM et al. Genetic heterogeneity of Usher syndrome type II. localization to chromosome 5q. *J Med Genet* 2000; 37: 256–262.
111. Ben-Yosef T, Ness SL, Madeo AC et al. A prevalent mutation of PCDH15 among Ashkenazi, Jews with the type I Usher syndrome. *N Engl J Med* 2003; 348: 1664–1670.